Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:18 PM
Ignite Modification Date:
2025-12-24 @ 7:18 PM
NCT ID:
NCT06766903
Eligibility Criteria:
Inclusion Criteria:
* Breast cancer diagnosed
* With/without chemotherapy treatment
* Normal weight body mass index \[BMI\] 18.6 to 24.9 or overweight/obesity condition by BMI 25.0 to 39.9 kg/m2
* Age 30 to 75 years
* With/without other associated co-morbidities (diagnosed of elevated fasting glucose, prediabetes or diabetes, hypertension or prehypertension, or metabolic syndrome, fatty liver or hypercholesterolemia or screened by our research team).
* With/without hormonal therapy
* With/without other pharmacotherapy for specific muscle-groups such as morphine patches, morphine droplets or other pharmacological therapy for SOS pain treatment
Exclusion Criteria:
* History of abnormal ECG
* Diagnosis of other cardio-vascular condition/history other than hypertension, vasculopathy
* History of uncontrolled stage 3 of hypertension or hypertensive crisis
* Diabetes complications such as varicose ulcers, nephropathies
* Skeletal muscle abnormalities (e.g., knee, or hip arthrosis, muscle pain)
* Using weight loss treatment/pharmacotherapy or being active in exercise training programs (or within the past three months)
* Use other pharmacotherapy that can influence body weight loss,
* Respiratory disease type (chronic obstructive disease)
* Kidney disease
* Pregnancy
* Smoking behaviour or dependence on other substances.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
30 Years
Maximum Age:
75 Years
Study:
NCT06766903
Study Brief:
Protocol Section:
NCT06766903